Advaxis to fund combination trial with AstraZeneca's MEDI4736

22 Jul 2014

• By Sukaina Virji

AstraZeneca's MedImmune subsidiary has entered a clinical trial collaboration with US biotechnology company Advaxis aimed at boosting the companies' distinct investigational cancer immunotherapies by administering them together.

Advaxis to fund combination trial with AstraZeneca's MEDI4736

More from Anticancer

More from Therapy Areas